Dimethyl sulfoxide's impact on epileptiform activity in a mouse model of chronic temporal lobe epilepsy

Epilepsy Res. 2023 Nov:197:107235. doi: 10.1016/j.eplepsyres.2023.107235. Epub 2023 Sep 30.

Abstract

In the quest for novel treatments for patients with drug-resistant seizures, poor water solubility of potential drug candidates is a frequent obstacle. Literature indicated that the highly efficient solvent dimethyl sulfoxide (DMSO) may have a confounding influence in epilepsy research, reporting both pro- and antiepileptic effects. In this study, we aim to clarify the effects of DMSO on epileptiform activity in one of the most frequently studied models of chronic epilepsy, the intrahippocampal kainic acid (IHKA) mouse model, and in a model of acute seizures. We show that 100 % DMSO (in a volume of 1.5 µl/g corresponding to 1651 mg/kg) causes a significant short-term anti-seizure effect in epileptic IHKA mice of both sexes, but does not affect the threshold of acute seizures induced by pentylenetetrazol (PTZ). These findings highlight that the choice of solvent and appropriate vehicle control is crucial to minimize undesirable misleading effects and that drug candidates exclusively soluble in 100 % DMSO need to be modified for better solubility already at initial testing.

Keywords: DMSO; Dimethyl sulfoxide; Intrahippocampal kainic acid model; Pentylenetetrazol-induced acute seizures; Temporal lobe epilepsy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Dimethyl Sulfoxide / adverse effects
  • Disease Models, Animal
  • Epilepsy*
  • Epilepsy, Temporal Lobe* / chemically induced
  • Epilepsy, Temporal Lobe* / drug therapy
  • Female
  • Hippocampus
  • Humans
  • Kainic Acid / toxicity
  • Male
  • Mice
  • Solvents / adverse effects

Substances

  • Dimethyl Sulfoxide
  • Solvents
  • Kainic Acid